Menopause delayed and symptoms decreased by Vitamin D - many studies

16+ Vitamin D Life pages having MENOPAUSE etc in the title

Vitamin D Life - Risk of hot flashes decreased by vitamin D, vegan diet, etc.

Vitamin D Life - The Role of Vitamin D in Menopausal Medicine – Jan 2016

Vitamin D Life - Age of menopause increases if add vitamin D or UVB

Might menopause symptom severity be reduced by Vitamin D? - May 2026

Short answer: the observational signal is suggestive, but the randomized evidence is mostly null — with one interesting exception. The catch is that the null trials were poorly designed to detect an effect, so the question isn't really settled in the way the headlines imply.

What the big RCT found. The dominant data point is the WHI Calcium/Vitamin D arm, which is what most "vitamin D doesn't help menopause" coverage rests on. Supplementation with 1000 mg of calcium plus 400 IU of vitamin D did not influence menopause-related symptoms over an average of 5.7 years among postmenopausal women with an average age of 64. There was no difference in sleep disturbance, emotional well-being, or energy/fatigue versus placebo, and the same null held for hot flashes and night sweats individually. A companion cross-sectional analysis of ~530 women with measured 25(OH)D also found no association between baseline vitamin D level and symptom burden.

The design limitations matter a lot here, and they're exactly the credibility-flags worth putting on a wiki page: the dose was only 400 IU (trivial by your standards), women were enrolled at a mean age of 64 — typically years past the symptomatic transition — calcium co-administration confounds the vitamin D signal, and crucially the trial did not select for deficiency at baseline. As the menopausal-health reviews note, the RCT evidence is not robust because many studies did not consider whether people were deficient at baseline, and there's high heterogeneity in dosage, calcium co-administration, and duration. A correction trial in already-replete women is structurally unlikely to show benefit.

The authoritative current stance. The 2023 EMAS (European Menopause and Andropause Society) position statement is the cleanest summary of where the field landed. Their conclusion: vitamin D deficiency may have a negative impact on some aspects such as sleep disturbances, depression, sexual function, and joint pains, but vitamin D supplementation has no effect on these — except for vulvovaginal atrophy. They go further and state plainly that vitamin D supplementation is not recommended for postmenopausal symptom relief.

The exception worth noting. Vulvovaginal atrophy is the one symptom domain with a positive supplementation signal. EMAS specifies it responds at relatively high doses, i.e., 40,000–60,000 IU/week orally or 1000 IU/day as a vaginal suppository. The local vaginal-suppository route is the more mechanistically interesting one for your audience, since it sidesteps the systemic-replete confound.

Why a link is biologically plausible anyway. The observational and mechanistic case isn't nothing, which is why the question keeps getting revisited. Vitamin D can protect against experimental serotonin depletion, and a menopausal decline in serotonin — a neurotransmitter with known effects on thermoregulation — may contribute to hot flashes. There's also an estrogen–vitamin D coupling that's directly relevant: because estrogen increases the activity of the enzyme responsible for activating vitamin D, the fall in estrogen during the transition could uncover previously subclinical vitamin D deficiency. And the symptom overlap is real — mood disturbance and musculoskeletal complaints associated with vitamin D deficiency resemble symptoms women experience during the menopausal transition. The most-cited positive human signal is small and off-target: breast cancer patients on aromatase inhibitors with 25(OH)D above 66 ng/ml had fewer hot flashes than women with lower levels, though AI-induced hot flashes aren't identical to menopausal VMS.

The trial that would actually answer this is the Kaiser/OHSU design that enrolled only vitamin D–insufficient early-postmenopausal women and titrated them to sufficiency — testing the hypothesis that insufficient women randomized to supplementation and titrated to sufficiency for 2 months will have fewer hot flashes, mood, and musculoskeletal complaints than usual care. That's the correct framing: not "does vitamin D treat menopause" but "does correcting deficiency in symptomatic, deficient perimenopausal women reduce severity." To my knowledge that specific question still lacks an adequately powered, deficiency-targeted, high-dose RCT — which is the honest gap to flag rather than overclaiming either direction.

So for a Vitamin D Life page, the defensible bottom line is: supplementation is not a symptom treatment per the trial evidence, the deficiency-correction hypothesis remains genuinely untested at adequate dose, and vulvovaginal atrophy is the lone evidence-backed symptomatic benefit.

Claude AI May 2026

$1.8 billion = cost of workdays missed due to Menopause Symptoms - June 2023

Impact of Menopause Symptoms on Women in the Workplace

Mayo Clinic Proceedings Vol 98, Issue 6, June 2023, Pages 833-845 https://doi.org/10.1016/j.mayocp.2023.02.025

Stephanie S. Faubion MD, MBA a d, Felicity Enders PhD b, Mary S. Hedges MD c, Rajeev Chaudhry MBBS, MPH d e, Juliana M. Kling MD, MPH d f, Chrisandra L. Shufelt MD, MS a d, Mariam Saadedine MD a d, Kristin Mara MS b, Joan M. Griffin PhD g, Ekta Kapoor MBBS d h i

Objective

To evaluate the impact of menopause symptoms on work outcomes and to assess the estimated economic impact.

Patients and Methods

Women aged 45 to 60 years receiving primary care at 1 of the 4 Mayo Clinic sites were invited to participate in a survey study (Hormones and ExpeRiences of Aging) from March 1 through June 30, 2021. A total of 32,469 surveys were sent, with 5219 responses (16.1% response rate). Of the 5219 respondents, 4440 (85.1%) reported current employment information and were included in the study. The primary outcome was self-reported adverse work outcomes related to menopause symptoms assessed by the Menopause Rating Scale (MRS).

Results

The mean age of the 4440 participants was 53.9±4.5 years, with the majority being White (4127 [93.0%]), married (3398 [76.5%]), and educated (2632 [59.3%] college graduate or higher); the mean total MRS score was 12.1, signifying moderate menopause symptom burden. Overall, 597 women (13.4%) reported at least one adverse work outcome due to menopause symptoms; 480 women (10.8%) reported missing work in the preceding 12 months (median, 3 days missed). The odds of reporting an adverse work outcome increased with increasing menopause symptom severity; women in the highest quartile of total MRS scores were 15.6 (95% CI, 10.7 to 22.7; P<.001) times more likely to have an adverse work outcome vs those in the first quartile. Based on workdays missed due to menopause symptoms, we estimate an annual loss of $1.8 billion in the United States .

Conclusion

This large cross-sectional study identified a major negative impact of menopause symptoms on work outcomes and the need to improve medical treatment for these women and make the workplace environment more supportive. Additional studies are needed to confirm these findings in larger and more diverse groups of women.

Section snippets

Study Design and Participants

We conducted a one-time survey study among women aged 45 to 60 years receiving primary care at 1 of 4 Mayo Clinic sites—Rochester, Minnesota; Scottsdale, Arizona; Jacksonville, Florida; and Mayo Clinic Health System, Northwest Wisconsin. The women were invited to complete a questionnaire between March 1 and June 30, 2021, that aimed to assess their menopause experiences and their perceptions about the care they received. The questionnaire assessed menopause symptoms, the impact of these...

Participants

Of the 32,469 surveys sent, 5219 responses were received (16.1%); 4440 (85.1%) of the respondents reported current employment and were included in the study. The demographic characteristics of the women in the study are summarized in Table 1. The mean age of the 4440 participants was 53.9±4.5 years, and the majority were White (4127 [93.0%]), married (3398 [76.5%]), and educated (2632 [59.3%] college graduate or higher). The mean total MRS score was 12.1, signifying moderate menopause symptom...

Discussion

To our knowledge, this is the largest study to date examining the impact of menopause symptoms on work outcomes. Employed US women receiving primary care at a large medical center across 4 geographic locations reported a substantial menopause symptom burden and a negative impact of these symptoms on work outcomes. Women who reported adverse work outcomes had a higher BMI and were less likely to be married or to consume alcohol regularly compared with those without an adverse work outcome. The...

Conclusion

Women are a vital part of the global workforce and economy. This study identified an association between menopause symptoms and adverse work outcomes, including lost work productivity. The severity of menopause symptoms strongly predicted the odds of an adverse work outcome. Based on this analysis, the estimated annual cost associated with lost days of work related to menopause symptoms among US women aged 45 to 60 years is $1.8 billion. Racial and ethnic differences were identified, with Black ...

43 References

G. Jack et al. Menopause in the workplace: what employers should be doing Maturitas (2016)
A. Griffiths et al. Menopause and work: an electronic survey of employees' attitudes in the UK Maturitas (2013)
M. Evandrou et al. Menopausal transition and change in employment: evidence from the National Child Development Study Maturitas (2021)
R.A.M. Hammam et al. Menopause and work—the experience of middle-aged female teaching staff in an Egyptian governmental faculty of medicine Maturitas (2012)
C. Hardy et al. What do working menopausal women want? a qualitative investigation into women's perspectives on employer and line manager support Maturitas (2017)
C.L. Kracht et al. It just seems like people are talking about menopause, but nobody has a solution": a qualitative exploration of menopause experiences and preferences for weight management among Black women Maturitas (2022)
N.F. Woods et al. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives Am J Med (2005)
M. Rees et al. Global consensus recommendations on menopause in the workplace: a European Menopause and Andropause Society (EMAS) position statement Maturitas (2021)
etc

UK is considering making severe menopause a disability - Feb 2024

Washington Post

113+ studies have Menopause and Vitamin D in the title (as of May 2026)

Google Scholar Some sample studies

Menopause, Metabolism, And the Vitamin D Connection: A Comprehensive Review - 2025
Relationship between Vitamin D Deficiency and Menopause-Associated Symptoms in Postmenopausal Women - 2025
Relationship between vitamin D levels and age of menopause and reproductive lifespan: Analysis based on the National health and nutrition examination survey (NHANES) 2001–2018 - Oct 2023 https://doi.org/10.1016/j.ejogrb.2023.09.003
Determinants and Effects of Vitamin D Supplementation in Postmenopausal Women: A Systematic Review - Jan 2023 https://doi.org/10.3390/nu15030685 FREE PDF
The role of vitamin D in menopausal women’s health - June 2023 https://doi.org/10.3389/fphys.2023.1211896 FREE PDF
Vitamin D supplementation after the menopause - June, 2020 https://doi.org/10.1177/2042018820931291 FREE PDF
Effect of Vitamin D on the Vaginal Health of Menopausal Women: A Systematic Review- Dec 2019 DOI: https://doi.org/10.6118/jmm.19194 FREE PDF
EMAS position statement: Vitamin D and menopausal health - March 2023 FREE PDF
Vitamin D and the Immune System in Menopause: A Review - Dec 2021 https://doi.org/10.6118/jmm.21011 FREE PDF
Vitamin D, menopause, and aging: quo vadis? - Nov 2019 https://doi.org/10.1080/13697137.2019.1682543
Vitamin D supplementation after the menopause - 2020 https://doi.org/10.1177/2042018820931291 FREE PDF